GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Raptor Pharmaceutical Corp (NAS:RPTP) » Definitions » Beneish M-Score

Raptor Pharmaceutical (Raptor Pharmaceutical) Beneish M-Score : 0.00 (As of May. 05, 2024)


View and export this data going back to 1999. Start your Free Trial

What is Raptor Pharmaceutical Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

The historical rank and industry rank for Raptor Pharmaceutical's Beneish M-Score or its related term are showing as below:

During the past 13 years, the highest Beneish M-Score of Raptor Pharmaceutical was 0.00. The lowest was 0.00. And the median was 0.00.


Raptor Pharmaceutical Beneish M-Score Historical Data

The historical data trend for Raptor Pharmaceutical's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Raptor Pharmaceutical Beneish M-Score Chart

Raptor Pharmaceutical Annual Data
Trend Dec06 Dec07 Dec08 Aug09 Aug10 Aug11 Aug12 Dec13 Dec14 Dec15
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -4.55 -4.14 49.59 -0.51 1.30

Raptor Pharmaceutical Quarterly Data
Aug11 Nov11 Feb12 May12 Aug12 Nov12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.88 -2.59 1.30 0.57 2.10

Competitive Comparison of Raptor Pharmaceutical's Beneish M-Score

For the Biotechnology subindustry, Raptor Pharmaceutical's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Raptor Pharmaceutical's Beneish M-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Raptor Pharmaceutical's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Raptor Pharmaceutical's Beneish M-Score falls into.



Raptor Pharmaceutical Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Raptor Pharmaceutical for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.9214+0.528 * 0.9797+0.404 * 12.9075+0.892 * 1.2963+0.115 * 0.7805
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.9673+4.679 * -0.104531-0.327 * 0.7038
=2.10

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Jun16) TTM:Last Year (Jun15) TTM:
Total Receivables was $15.7 Mil.
Revenue was 32.045 + 27.47 + 24.667 + 25.787 = $110.0 Mil.
Gross Profit was 27.097 + 23.139 + 21.039 + 23.156 = $94.4 Mil.
Total Current Assets was $156.8 Mil.
Total Assets was $354.9 Mil.
Property, Plant and Equipment(Net PPE) was $7.5 Mil.
Depreciation, Depletion and Amortization(DDA) was $1.9 Mil.
Selling, General, & Admin. Expense(SGA) was $80.1 Mil.
Total Current Liabilities was $43.9 Mil.
Long-Term Debt & Capital Lease Obligation was $90.2 Mil.
Net Income was -14.019 + -41.585 + -17.003 + -14.588 = $-87.2 Mil.
Non Operating Income was 0.179 + -0.213 + 0.057 + -0.098 = $-0.1 Mil.
Cash Flow from Operations was -5.126 + -21.925 + -12.276 + -10.691 = $-50.0 Mil.
Total Receivables was $13.2 Mil.
Revenue was 23.332 + 20.453 + 17.286 + 23.764 = $84.8 Mil.
Gross Profit was 20.692 + 16.731 + 14.096 + 19.847 = $71.4 Mil.
Total Current Assets was $242.8 Mil.
Total Assets was $261.3 Mil.
Property, Plant and Equipment(Net PPE) was $7.6 Mil.
Depreciation, Depletion and Amortization(DDA) was $1.4 Mil.
Selling, General, & Admin. Expense(SGA) was $63.9 Mil.
Total Current Liabilities was $35.2 Mil.
Long-Term Debt & Capital Lease Obligation was $105.0 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(15.727 / 109.969) / (13.167 / 84.835)
=0.143013 / 0.155207
=0.9214

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(71.366 / 84.835) / (94.431 / 109.969)
=0.841233 / 0.858706
=0.9797

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (156.786 + 7.471) / 354.939) / (1 - (242.818 + 7.568) / 261.26)
=0.537225 / 0.041621
=12.9075

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=109.969 / 84.835
=1.2963

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(1.42 / (1.42 + 7.568)) / (1.896 / (1.896 + 7.471))
=0.157988 / 0.202413
=0.7805

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(80.087 / 109.969) / (63.872 / 84.835)
=0.728269 / 0.752897
=0.9673

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((90.17 + 43.923) / 354.939) / ((105 + 35.234) / 261.26)
=0.377792 / 0.53676
=0.7038

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-87.195 - -0.075 - -50.018) / 354.939
=-0.104531

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Raptor Pharmaceutical has a M-score of 2.10 signals that the company is likely to be a manipulator.


Raptor Pharmaceutical Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Raptor Pharmaceutical's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Raptor Pharmaceutical (Raptor Pharmaceutical) Business Description

Traded in Other Exchanges
N/A
Address
Raptor Pharmaceutical Corp was initially incorporated in Nevada on July 29, 1997 as Axonyx Inc. In October 2006, Axonyx Inc. and its then wholly-owned subsidiary completed a reverse merger, business combination with TorreyPines Therapeutics, Inc., reincorporated in Delaware and changed the corporate name to 'TorreyPines Therapeutics, Inc. On September 28, 2009, the Company name was again changed from TorreyPines Therapeutics, Inc., to Raptor Pharmaceutical Corp. It is a biopharmaceutical company focused on developing and commercializing transformative treatments for people affected by rare and debilitating diseases. The Company's product PROCYSBI cysteamine bitartrate, delayed-release capsules received marketing approval from the U.S. Food and Drug Administration on April 30, 2013 for the management of nephropathic cystinosis in adults and children six years and older. The European equivalent, PROCYSBI gastro-resistant hard capsules of cysteamine, received marketing authorization on September 6, 2013 from the European Commission, as an orphan medicinal product for the management of nephropathic cystinosis for marketing in the European Union. PROCYSBI received 7 years and 10 years of market exclusivity as an orphan drug in the U.S. and the EU, respectively. PROCYSBI is an approved therapy for the management of nephropathic cystinosis, a rare, life-threatening metabolic lysosomal storage disorder that causes the rapid, toxic accumulation of cystine in all cells, tissues and organs in the body. PROCYSBI capsules contain cysteamine bitartrate in the form of microspheronized beads that are individually coated to create delayed and extended-release properties, allowing patients to maintain consistent therapeutic systemic drug levels over a 12-hour dosing period. Cysteamine is a molecule generated in the cell during the metabolism of cysteine. The Company's pipeline products include; its proprietary delayed-release form of cysteamine, or RP103. The Company currently has product candidates in clinical development designed to potentially treat Huntington's disease, Non-alcoholic fatty liver disease, Leigh syndrome and other mitochondrial disorders and aldehyde dehydrogenase deficiency. The Company's preclinical programs are based upon bioengineered novel drug candidates that are designed to target cancer and other diseases. Its other clinical-stage product candidates include: Convivia its proprietary oral formulation of 4-methylpyrazole, for the potential management of acetaldehyde toxicity due to alcohol consumption by individuals with aldehyde dehydrogenase, or ALDH2, deficiency, an inherited metabolic disorder. With respect to any of the Company's product candidates for which it obtain FDA approval, it will be subject to ongoing FDA obligations and continued regulatory review, which may result in additional expense.
Executives
Raymond Anderson director C/O MONOPAR THERAPEUTICS INC., 1000 SKOKIE BLVD., SUITE 350, WILMETTE IL 60091
Krishna R Polu officer: Chief Medical Officer C/O RAPTOR PHARMACEUTICAL CORP, 7 HAMILTON LANDING, SUITE 100, NOVATO CA 94949
Michael P Smith officer: Chief Financial Officer 887 GREAT NORTHERN WAY VANCOUVER A1 V5T 4T5
Suzanne Louise Bruhn director C/O AEGLEA BIOTHERAPEUTICS, INC., 901 S. MOPAC EXPRESSWAY, SUITE 250, AUSTIN TX 78746
Georges Gemayel director 550 HILLS DRIVE, BEDMINSTER NJ 07921
Llew Keltner director 7 HAMILTON LANDING, SUITE 100, NOVATO CA 94949
Christopher M Starr director C/O MONOPAR THERAPEUTICS INC, 1000 SKOKIE BLVD., SUITE 350, WILMETTE IL 60091
David Happel officer: Chief Commercial Officer 7 HAMILTON LANDING, SUITE 100, NOVATO CA 94949
Julie Smith director, officer: President and CEO C/O RAPTOR PHARMACEUTICAL CORP, 9 COMMERCIAL BLVD, SUITE 200, NOVATO CA 94949
Anthony Gregg Lapointe director PO BOX 83216, GAITHERSBURG MD 20883-3216
Erich Sager director 9 COMMERCIAL BLVD., SUITE 200, NOVATO CA 94949
Georgia Erbez officer: Chief Financial Officer 6300 DUMBARTON CIRCLE, FREMONT CA 94555
Vijay B Samant director 10390 PACIFIC CENTER COURT, SAN DIEGO CA 92121
Timothy P Walbert director 1033 SKOKIE BOULEVARD, SUITE 355, NORTHBROOK IL 60062
Patrice Rioux other: CMO, Raptor Therapeutics C/O MONOPAR THERAPEUTICS INC, 1000 SKOKIE BLVD., SUITE 350, WILMETTE IL 60091

Raptor Pharmaceutical (Raptor Pharmaceutical) Headlines

No Headlines